
Tumor markers are biological molecules produced by malignant cells or by the body in response to cancer, and they serve as essential tools for monitoring disease progression, evaluating treatment response, and detecting recurrence. Among the most widely used markers are cancer antigen 125 (CA-125), carcinoembryonic antigen (CEA), and human epidermal growth factor receptor 2 (HER2). Each marker has distinct clinical applications, analytical characteristics, and limitations that influence its utility in oncology. This review provides a comparative analysis of CA-125, CEA, and HER2, focusing on their roles in cancer monitoring, treatment selection, and the practical considerations for assay development and bioanalysis.
Introduction to Tumor Markers in Oncology
Serum and tissue-based tumor markers have become integral components of cancer management over the past several decades. Their principal applications include aiding in diagnosis, stratifying patients by risk, monitoring response to therapy, and detecting early recurrence. However, no single marker exhibits perfect sensitivity and specificity; therefore, clinicians must interpret marker levels in the context of the patient's clinical presentation, imaging findings, and other laboratory data. The selection of an appropriate marker depends on the tumor type, stage, and the intended clinical question. CA-125, CEA, and HER2 represent three paradigms: a serum marker for ovarian cancer, a serum marker for colorectal and other epithelial malignancies, and a tissue-based receptor that guides targeted therapy in breast cancer, respectively.
Understanding the biology, assay methodologies, and performance characteristics of these markers is critical for both clinical practice and translational research. The following sections detail each marker's clinical applications, strengths, and limitations, followed by a comparative analysis of their diagnostic utility and a discussion of bioanalytical considerations for developing and validating tumor marker assays.
CA-125: Applications in Ovarian Cancer and Limitations
Cancer antigen 125 (CA-125) is a high-molecular-weight glycoprotein encoded by the MUC16 gene and is expressed on the surface of ovarian epithelial cells. It is the most extensively studied and routinely used serum biomarker for epithelial ovarian cancer. The normal reference value for CA-125 is typically less than 35 U/mL, and elevated levels are observed in approximately 80% of women with advanced ovarian cancer. In clinical practice, CA-125 is employed for monitoring response to chemotherapy, detecting disease recurrence after primary treatment, and differentiating malignant from benign pelvic masses when used in combination with imaging modalities.
Reported sensitivity of CA-125 for ovarian cancer detection is 78.9%, with a specificity of 86.9%. However, these values are not uniform across all stages; sensitivity is markedly lower for early-stage disease, limiting its utility as a screening tool. Large prospective trials, such as the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, have demonstrated that annual CA-125 screening does not reduce ovarian cancer mortality and leads to unnecessary surgical interventions due to false-positive results. Elevated CA-125 levels can also occur in benign conditions including endometriosis, pelvic inflammatory disease, pregnancy, uterine fibroids, and liver cirrhosis, which complicates interpretation in premenopausal women.
In the context of breast cancer, CA-125 has been investigated as a potential prognostic marker, but its performance is suboptimal. A 2025 study reported that CA-125 has a sensitivity of only 29.8% for detecting breast cancer, with limited correlation between marker levels and specific tumor characteristics. Patients with triple-negative breast cancer tend to exhibit higher CA-125 levels compared to those with luminal A, luminal B, or HER2-positive subtypes, but the marker is not considered sufficiently discriminative for routine clinical use. Consequently, CA-125 remains primarily indicated for ovarian cancer management, and its role in breast cancer is not established.
CEA: Role in Colorectal Cancer Monitoring
Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion and is normally produced during fetal development. In adults, CEA serum levels are low, but they become elevated in several epithelial malignancies, most notably colorectal cancer. CEA is the classic tumor marker for colorectal cancer and is recommended by international guidelines for post-surgical surveillance. Serial CEA measurements are used to detect recurrence, monitor response to therapy, and assess prognosis. A rising CEA level after curative resection often prompts imaging studies to identify metastatic disease before clinical symptoms appear.
The diagnostic performance of CEA varies by cancer type. For colorectal cancer, CEA has moderate sensitivity (around 40–60%) but high specificity, particularly when the upper limit of normal is set at 5 ng/mL. In breast cancer, however, CEA demonstrates low sensitivity (<10%) while="" maintaining="" high="" specificity="">98%), making it a poor screening marker but potentially useful as an adjunct in combination with other markers such as CA 15-3. Elevated CEA levels are not specific to malignancy; they can be found in smokers, patients with chronic obstructive pulmonary disease, inflammatory bowel disease, pancreatitis, and benign liver disease. Therefore, clinical interpretation must account for these confounding factors.
Advances in CEA-targeted therapies have further highlighted the importance of this marker. CEA is now being explored as a target for antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. The expression of CEA on the surface of tumor cells makes it an attractive candidate for theranostic applications. Additionally, CEA measurement is used in the monitoring of other malignancies, including gastric, pancreatic, lung, and breast cancers, though its utility in these settings is less established than in colorectal cancer. The development of high-sensitivity immunoassays and the integration of CEA with other biomarkers have improved the clinical value of this longstanding marker.
HER2: Significance in Breast Cancer Treatment Selection
Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene. Unlike CA-125 and CEA, which are measured in serum, HER2 status is determined by immunohistochemistry (IHC) and/or in situ hybridization (ISH) on tumor tissue. HER2 overexpression or gene amplification occurs in approximately 15–20% of invasive breast cancers and is associated with aggressive tumor biology, higher recurrence rates, and shorter overall survival in the absence of targeted therapy. The determination of HER2 status is mandatory for all newly diagnosed breast cancer patients because it directly informs treatment selection with HER2-directed agents such as trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan.
The clinical utility of HER2 extends beyond prognosis; it is one of the most successful examples of a predictive biomarker in oncology. Patients with HER2-positive breast cancer derive substantial benefit from anti-HER2 therapies, which have transformed the natural history of this subtype. However, HER2 status can change during disease progression or after neoadjuvant therapy, necessitating repeat biopsy of recurrent or metastatic lesions. There is also emerging interest in serum HER2 extracellular domain (ECD) as a dynamic marker for monitoring treatment response, although it is not yet standard practice. The interpretation of HER2 results requires rigorous standardization of assays, as IHC scoring (0, 1+, 2+, 3+) and ISH ratios are subject to inter-observer variability and require adherence to ASCO/CAP guidelines.
In addition to breast cancer, HER2 amplification or overexpression is observed in gastric, gastroesophageal junction, and a subset of lung, bladder, and ovarian cancers. In these contexts, HER2 status similarly guides therapy, though the predictive value may differ. The development of novel HER2-targeted agents and the expansion of indications for existing drugs underscore the importance of accurate HER2 assessment. Ongoing research into liquid biopsy approaches, including circulating tumor DNA (ctDNA) and circulating tumor cells, aims to provide a non-invasive alternative for HER2 evaluation, but tissue-based testing remains the gold standard.
Key Differences Between CA-125, CEA, and HER2 Tumor Markers
- CA-125: Serum glycoprotein for ovarian cancer monitoring; sensitivity 78.9%, specificity 86.9%; not recommended for screening due to elevations in benign conditions.
- CEA: Serum glycoprotein for colorectal cancer surveillance; high specificity (>98%) but low sensitivity for early-stage detection; also elevated in smokers and inflammatory conditions.
- HER2: Tissue-based receptor for breast cancer treatment selection; assessed by IHC/ISH; predictive biomarker for trastuzumab, pertuzumab, and T-DM1 therapies.
- Combination Panels: CA-125 + HE4 (ROMA) for ovarian cancer risk stratification; CEA + CA 15-3 for improved breast cancer monitoring.
| Types | Typical Use Case | Key Advantages | Main Limitations |
| Serum glycoprotein (CA-125) | Ovarian cancer monitoring, treatment response, recurrence detection | High sensitivity (78.9%) and specificity (86.9%) for ovarian cancer; widely used for monitoring therapy and detecting recurrence. | Elevated in benign conditions (endometriosis, pregnancy, fibroids); low sensitivity for early-stage disease; not recommended for screening. |
| Serum glycoprotein (CEA) | Colorectal cancer monitoring, post-surgical surveillance, therapy response | High specificity (>98%) for colorectal cancer; established for recurrence monitoring; also used in lung, breast, pancreatic cancers. | Low sensitivity (<10% for breast cancer); elevated in smokers, inflammation, benign liver disease; not diagnostic for primary cancer. |
| Tissue receptor (HER2/neu) | Breast cancer treatment selection (targeted therapy: trastuzumab, pertuzumab, T-DM1) | Critical for guiding HER2-directed therapy; strong prognostic and predictive value; assessed by IHC and FISH. | Requires tissue biopsy; dynamic changes during treatment; inter-observer variability in IHC scoring; not a serum marker. |
| Combination panels (e.g., CA-125 + HE4, CEA + CA15-3) | Improved diagnostic accuracy in specific cancers (ovarian, breast) | Enhanced sensitivity and specificity; reduced false-positive rate; recommended in clinical guidelines. | Increased complexity and cost; lack of standardization across platforms; need for multi-marker validation studies. |
Comparative Analysis: Sensitivity, Specificity, and Clinical Utility
When comparing CA-125, CEA, and HER2, it is essential to recognize that each marker occupies a distinct niche in oncology. CA-125 is primarily a serum marker for ovarian cancer, with moderate sensitivity and specificity that are adequate for monitoring but insufficient for screening. CEA, also a serum marker, is most valuable for colorectal cancer surveillance and has high specificity but low sensitivity for early-stage detection. HER2, in contrast, is a tissue-based predictive marker that is indispensable for therapy selection in breast cancer and is not measured in serum for routine clinical decisions.
In terms of diagnostic performance, CA-125 has a reported sensitivity of 78.9% and specificity of 86.9% for ovarian cancer, whereas CEA demonstrates sensitivity below 10% for breast cancer but specificity above 98%. For colorectal cancer, CEA sensitivity improves to 40–60% with high specificity. HER2 testing by IHC has a sensitivity and specificity exceeding 90% when performed according to standardized guidelines, but false positives and negatives can occur due to assay variability and tissue fixation issues. The combination of markers, such as CA-125 with HE4 for ovarian cancer or CEA with CA 15-3 for breast cancer, can improve overall diagnostic accuracy by reducing false-positive rates and capturing complementary information.
Clinical utility also differs. CA-125 and CEA are used for longitudinal monitoring of disease status and are often measured serially to detect changes that may indicate progression or recurrence. HER2 status is typically determined at diagnosis and again at recurrence if a change in therapy is contemplated. The choice of marker should be guided by the tumor type, the clinical question (monitoring vs. treatment selection), and the availability of validated assays. No single marker is sufficient for all scenarios, and multimodal approaches incorporating imaging, histology, and molecular profiling remain the standard of care.
Considerations for Assay Development and Bioanalysis Support
Developing and validating assays for tumor markers such as CA-125, CEA, and HER2 requires rigorous attention to analytical performance, preanalytical variables, and regulatory compliance. For serum markers, immunoassays (e.g., ELISA, chemiluminescence, electrochemiluminescence) are the most common platforms. Key parameters include sensitivity, specificity, linearity, precision, accuracy, and robustness. Method comparison studies are essential because different commercial assays may yield different absolute values, affecting clinical decision-making. For example, a 2023 study comparing breast cancer protein tumor markers across platforms found significant method-dependent variability, underscoring the need for harmonization and use of the same assay for serial monitoring of a given patient.
Preanalytical factors such as sample type (serum vs. plasma), collection tube, clotting time, centrifugation conditions, and storage temperature can markedly influence marker levels. For CA-125 and CEA, hemolyzed or lipemic samples may produce spurious results. For HER2 testing by IHC or ISH, tissue fixation (formalin vs. alternative fixatives), section thickness, antigen retrieval conditions, and antibody clone selection all affect staining intensity and interpretation. Standard operating procedures and quality control materials must be established to ensure reproducibility across batches and sites. Leveraging professional Bioanalysis Services can streamline assay development, qualification, and transfer to clinical laboratories.
Regulatory considerations also play a crucial role. In the United States, assays for tumor markers must comply with CLIA regulations for laboratory-developed tests (LDTs) or receive FDA clearance. In Europe, the In Vitro Diagnostic Regulation (IVDR) imposes stringent requirements on performance evaluation and clinical evidence. For drug development programs that incorporate tumor markers as companion diagnostics, close collaboration with regulatory agencies is necessary to align on the intended use and validation strategy. Large Molecule Bioanalysis and Small Molecule Bioanalysis capabilities can support the quantification of both protein biomarkers and therapeutic agents in pharmacokinetic/pharmacodynamic studies. Additionally, In Vitro Biology Services can aid in the characterization of target engagement and biomarker modulation. For tissue-based HER2 assessment, Protein Science Services provide expertise in antibody development, immunohistochemistry optimization, and multiplexed imaging. Integrating these specialized offerings ensures that tumor marker assays are robust, reproducible, and fit for their intended clinical or research purpose.
Practical Considerations for Clinical Implementation
When implementing tumor marker testing in clinical practice, several factors must be considered to maximize utility and minimize harm. First, the appropriate clinical context must be defined: CA-125 and CEA are best used for monitoring known disease, not for screening or diagnosis in asymptomatic individuals. Second, serial measurements are more informative than single values; trends over time provide greater sensitivity for detecting progression or recurrence. Third, clinicians must be aware of the many non-malignant causes of marker elevation, including benign gynecologic conditions for CA-125 and inflammatory states for CEA. Fourth, for HER2, repeat testing on metastatic biopsies is recommended because discordance rates between primary and recurrent tumors can reach 10–20%.
Quality assurance programs are essential for ensuring reliable results. Participation in external quality assessment schemes, use of certified reference materials, and regular calibration verification help maintain assay accuracy. In research settings, the use of surrogate markers and combination panels can improve diagnostic performance. For example, the Risk of Ovarian Malignancy Algorithm (ROMA) combines CA-125 with HE4 and menopausal status to stratify patients into high- and low-risk groups. Similarly, the Barcelona Clinic Liver Cancer (BCLC) algorithm incorporates alpha-fetoprotein (AFP) for hepatocellular carcinoma, but analogous models exist for other tumor types. The integration of tumor markers with radiological imaging and clinical risk factors remains the cornerstone of evidence-based cancer care.
Advances in technology, such as digital immunoassays, mass spectrometry-based proteomics, and liquid biopsy, are expanding the repertoire of tumor markers. However, the classical markers CA-125, CEA, and HER2 retain their relevance due to their extensive validation, established clinical utility, and widespread availability. Future developments will likely focus on refining assay specificity, developing multiplex panels, and incorporating novel biomarkers such as circulating tumor DNA and exosomal proteins. Until then, a thorough understanding of the strengths and limitations of these three markers will enable clinicians and researchers to use them effectively in cancer monitoring and treatment selection.
Our specialized Bioanalysis Services provide end-to-end support for tumor marker assay development, qualification, and clinical trial application. Whether you require Large Molecule Bioanalysis for monoclonal antibodies or Small Molecule Bioanalysis for companion diagnostics, our integrated platform ensures reliable data for your biomarker program. Complemented by In Vitro Biology Services and Protein Science Services, we offer comprehensive solutions to accelerate your oncology research.
Frequently Asked Questions
Q: What is the role of CA-125 in ovarian cancer monitoring?
CA-125 is a serum glycoprotein used primarily to monitor response to therapy and detect recurrence in ovarian cancer patients. While it has high sensitivity (78.9%) and specificity (86.9%) for ovarian cancer, it is not recommended for screening due to elevated levels in benign conditions such as endometriosis, pregnancy, and uterine fibroids. Serial measurement is standard practice for treatment monitoring.
Q: How is CEA used in colorectal cancer management?
Carcinoembryonic antigen (CEA) is a classic tumor marker for epithelial malignancies, particularly colorectal cancer. It is used for post-surgical surveillance to detect recurrence and monitor response to therapy. CEA has high specificity (>98%) but low sensitivity for early-stage disease. Elevated levels can also occur in smokers, inflammatory conditions, and benign liver disease, so it is interpreted in conjunction with imaging and clinical findings.
Q: Why is HER2 important for breast cancer treatment selection?
HER2 (human epidermal growth factor receptor 2) is a tissue receptor that drives aggressive tumor growth when overexpressed or amplified. Assessment of HER2 status by immunohistochemistry or in situ hybridization is essential for selecting patients who will benefit from targeted therapies such as trastuzumab, pertuzumab, and antibody-drug conjugates. HER2 status can change during disease progression, so re-biopsy may be needed.
Q: What are the limitations of using single tumor markers?
Single tumor markers often lack sufficient sensitivity and specificity for standalone diagnosis. For example, CA-125 is elevated in many benign gynecologic conditions, and CEA can be increased in non-malignant inflammation. Combining multiple markers (e.g., CA-125 with HE4, or CEA with CA15-3) improves diagnostic accuracy. No tumor marker is currently recommended for population screening due to false-positive rates and lack of early detection capability.
